Hemas Holdings Ltd. · CSELK:HHL.N0000
Hemas — Q2 FY23/24 Earnings Presentation
29 slides from Hemas's earnings presentation, 2023
Slide 1: Hemas Holdings PLC Investor Presentation Q2 FY23/24
Hemas Holdings PLC Investor Presentation- Q2 FY23/24
Slide 2: Who we are
Who we are Established in 1948, with a purpose of empowering families to live a better tomorrow, Hemas Holdings is one of Sri Lanka’s leading conglomerates listed in the Colombo Stock exchange with focused interest in Consumer and Healthcare. Key Milestones “Established Hemas Drugs Pvt 1948 Ltd” “IP
Slide 3: Implications of key macro economic parameters on Hemas
Implications of key macro economic parameters on Hemas Inflationary Pressure Appreciation of LKR Global Commodity prices “Reduced consumer demand across “ Favourable Impact of reduced prices “Positive impact from reduced RM the sectors amidst inflationary of key commodities was passed down costs and
Slide 4: Key strengths
BOM Group CEO Nomination & Governance Committee Human Related Party Resources & Transactions Board Remuneration Review Committee Committee Investment Group Audit Committee Committee Diversified and competent Presence in key defensive segments Leadership Team Healthcare and Consumer Sound Corporate G
Slide 5: Corporate Governance
Corporate Governance BOM Group CEO BOM (Board of Management) Nomination & Consists of the senior leadership team of 11 members - Heads of our 6 businesses and 5 leaders from Corporate Governance Office. BOM is responsible for formulation and implementation of Group strategic plan and ensures that th
Slide 6: Strategic Building Blocks
Strategic Building Blocks Building more from New within the core New business and Efficiencies the core and Adjacencies Internationalisation Accelerate current business Capturing new revenue Explore attractive Efficiency and productivity to efforts to drive higher value streams to further strengthen
Slide 7: New Product Launches during the Quarter
New Product Launches during the Quarter Home and Personal Care Pharmaceutical Manufacturing ‘Prasara’ body ‘Clogard’ Smart purifying tonic clean dual pack Additions to the ‘Gold’ and ‘Goya’ ‘TaZcip (Sitagliptin BP 50mg portfolio and 100mg) contract manufacturing for ‘Kolombo’ Pure Coconut ‘Cipla’ Oi
Slide 8: Financial Snapshot
Financial Snapshot EBIT By Segment (LKR million) 2,767 2,693 247 2,033 500 2,154 6M contribution to the Group 1,547 1,477 225 212 38% 1% 60% 230 1,211 1,147 10% 1,137 Revenue 668 53% 55% 1,393 1,616 EBIT 936 995 1,090 (252) (346) (410) (308) (574) Consumer Healthcare Mobility Healthcare Consumer Mob
Slide 9: Sector Performance Summary – Q2 FY 2023-24
Sector Performance Summary – Q2 FY 2023-24 Revenue Walk EBIT Walk (LKR Mn) (LKR Mn) 1,389 29,829 223 -163 1,402 12 -92 266 -253 27,119 2,693 2,767 Q2 FY 23 Consumer Healthcare Other Mobility Q2 FY 24 Q2 FY 23 Consumer Healthcare Other Mobility Q2 FY 24
Slide 10: Sector Performance Summary – 6M FY 2023-24
Sector Performance Summary – 6M FY 2023-24 Revenue Walk EBIT Walk (LKR Mn) (LKR Mn) 160 -211 709 -462 3,359 13 -126 58,951 4,724 4,920 3,744 51,960 6M FY 23 Consumer Healthcare Other Mobility 6M FY 24 6M FY 23 Consumer Healthcare Other Mobility 6M FY 24
Slide 11: Continuing Operation EPS – Q2 FY 2023-24
Continuing Operation EPS – Q2 FY 2023-24 EPS Walk (LKR Per Share) 0.12 0.06 -0.28 0.22 2.04 1.93 0.07 0.70 -0.31 -0.34 2.04 1.93 Q2 FY 23 NCI Operating Net Finance Income Tax Q2 FY 24 Q2 FY 23 Consumer Healthcare Other Mobility Q2 FY 24 Profit Cost
Slide 12: Continuing Operation EPS – 6M FY 2023-24
Continuing Operation EPS – 6M FY 2023-24 EPS Walk (LKR Per Share) 1.40 -0.33 -0.43 -0.51 0.33 -1.06 3.74 3.88 0.40 0.41 3.88 3.74 6M FY 23 Income Tax NCI Operating Net Finance 6M FY 24 6M FY 23 Consumer Healthcare Other Mobility 6M FY 24 Profit Cost
Slide 13: Capital Employed – Q2 FY 2023-24
Capital Employed – Q2 FY 2023-24 Sector Efficiency Capital Employed, ROCE, and EBIT by Sector 60% Mobility Consumer LKR 471.6 Mn LKR 2,623.5 Mn 50% 43.0% Healthcare 40% 39.3% LKR 2,706.3 Mn 30% Group ROCE :21.2% 20% 17.1% ROCE (%) 10% 0% 0 5 10 15 20 25 30 35 40 -10% -20% Capital Employed (LKR Bn) -
Slide 14: Consumer Brands
Consumer Brands Home and personal care - Sri-Lanka Consumer Brands - International Learning Segment
Slide 15: Consumer Brands
Consumer Brands Contribution to Group Sector Performance – 6M FY 2023-24 38% Key Highlights Revenue % Revenue (LKR Mn) 6M FY24 36% 13.9% 6M FY23 15,135 (YoY) • Amidst the inflationary pressure, 15,000 13,628 11,521 consumers continued to curtail 11,055 12,000 10,119 consumption and opt for value-for
Slide 16: Home and Personal Care – Sri Lanka
Home and Personal Care – Sri Lanka 8 Key categories with market Purpose-driven brands touching the lives of the Sri Lankan consumer leading positions Extensions to the ‘Velvet’ Portfolio Inclusive Strong roots Parenting Stronger Make a Celebrating Enabling Both parents together Positive Difference &
Slide 17: Home and Personal Care – International
Home and Personal Care – International Reach in Bangladesh 2 Geographies Locally led and localised in Bangladesh Bangladesh & West Bengal • All products are exclusively designed for Rural penetration by Bangladesh. 19.3% Hemas 2 Key categories • Extensive product portfolio with multiple value Hair O
Slide 18: Home and Personal Care – Sri Lanka and International
Home and Personal Care – Sri Lanka and International Sri Lanka International Revenue (LKR Mn) 12.9% Revenue Revenue (YoY) • Despite the rising macroeconomic challenges, HPC • Prices were maintained in line with the market, 8,830 8,446 8,606 8,803 Bangladesh arm witnessed volume-led growth 7,799 whil
Slide 19: Learning Segment
Learning Segment Revenue 6 Key categories • Atlas maintained its market share with volume- led growth. • ‘Homerun’ stationery line was launched as an Revenue (LKR Mn) accessible and cost-effective range for consumers. High Efficiency and 7,000 6,689 productivity through lean initiatives 6,000 Profit
Slide 20: Healthcare Sector
Healthcare Sector Pharmaceutical Import, Marketing and Distribution Pharmaceutical Manufacturing Hospitals
Slide 21: Healthcare
Healthcare Contribution to Group Sector Performance – 6M FY 2023-24 Revenue % 60% Revenue (LKR Mn) 8.4% Key Highlights (YoY) 6M FY24 6M FY23 62% 17,639 17,912 • Healthcare landscape continued to face 18,000 16,523 16,712 16,000 15,757 heightened difficulties, including 14,000 shortages of medicines
Slide 22: Pharmaceutical Import, Marketing, Distribution and Pharmaceutical Manufacturing
Pharmaceutical Import, Marketing, Distribution and Pharmaceutical Manufacturing Revenue • The Distribution vertical introduced over 20 new products during the quarter, ensuring availability and choice in many key therapuric segments. Revenue (LKR Mn) 8.7 % • Morison ventured into third party manufac
Slide 23: Hospitals
Hospitals Revenue 170+ Beds • Revenue increased under high occupancy at both the hospitals due to improved medical admissions. Revenue (LKR Mn) Revenue from key anchor specialties including 5.8.% • Nephrology, Cardiology and Gastro-Enterology (YoY) continued to witness double digit growth. 2,000 1,9
Slide 24: Mobility Sector
Mobility Sector Maritime Aviation
Slide 25: Mobility
Mobility Contribution to Group Sector Performance – 6M FY 2023-24 1% Revenue % Revenue (LKR Mn) Key Highlights -19.7% 6M FY24 2% (YoY) 6M FY23 500 469 384 418 376 • Stemming from lower base from the 345 previous year, the Port of Colombo observed a notable upturn, with transshipment and total throug
Slide 26: Our Commitment to ESG
Our Commitment to ESG ADDRESSING MARINE POLLUTION PROVIDING WIGS TO CANCER PATIENTS CREATING A SAFER WORLD CREATING EQUAL LEARNING OPPURTUNITY AND QUALITY EDUCATION EXPERIENCES 190,000+ KG 587 4,000+ 74,000+ Plastic Collected Women Families Children, Teachers and Parents TACKLING PERIOD POVERTY TACK
Slide 27: Sustainability Performance – Q2 FY24 vs Q2 FY23
Sustainability Performance – Q2 FY 24 vs Q2 FY23 Values of Fines for Non-Compliance Carbon Footprint (per Rs. Mn Revenue) 0.14MT with Laws and Regulations in the NONE Social Economic Area Water Consumption 1.7 Total Work-Related Injury Rate 0.1 (per Rs. Mn Revenue) 6.2% m3 (per 100 employee) Waste R
Slide 28: Corporate and BU Priorities
Focus on Personal care, Beauty and wellness Focus Areas with a drive for premiumiation and exploring underpenetrated Markets Corporate Priorities Strengthening value prepositions to grow market share Accelerating the M&A opportunities Accelerate exports and international expansion Consumer through O
Slide 29: Disclaimer / Thank You
Disclaimer The material in this presentation has been prepared by Hemas Holdings PLC (“Hemas”) and is general background information about Hemas’ activities current as at the date of this presentation. This information is given in summary form and does not purport to be complete. Information in this